Cytorex Biosciences Inc. (Cytorex), a South Florida biotechnology company with research and development facilities in Texas, announced today the publication of test results evaluating dermal irritation or corrosion caused by the ionic therapeutic agent Cytoreg® in rabbits in the Toxicology Reports Journal ELSEVIER.
"This method of toxicological evaluation, requires that the therapeutic agent Cytoreg®, is applied to the skin of an in vivo laboratory model to determine the likely effect of this ionic therapy on the corresponding tissue. Based on dose exposures of Cytoreg® at three dilutions; each animal received a 100%, 4% or 2% dilution in physiological saline. Three intact skin test sites per animal/concentration were evaluated for 72 hours, as established by the scientific method required by the US FDA pharmaceutical regulator for this type of testing. The ionic therapeutic agent, Cyotreg®, was then shown to be non-corrosive and was preliminarily assigned the U.S. EPA classification category IV (non-irritating to mildly irritating). (Non-irritating to mildly irritating) for all concentrations tested on the skin of the in vivo model," said William "Bill" Bauta, PhD consultant for Cytorex Biosciences Inc.
"We believe that we have taken a very important dermal safety step because of the toxicological safety data achieved. Also, because of the broad potential therapeutic uses of our technology in dermal pathologies of cancer, autoimmune diseases, diseases caused by pathogenic microorganisms and for its hemostasis power, we had considered performing this important dermal toxicological evaluation and therefore it was included in the development and research plan of Cytorex Biosciences Inc. With this result, we expect a very positive impact on the topical treatment of diabetic foot pathology, where we seek to have an impact on the reduction of the number of amputations", complemented William Jimenez, president of the company's board of directors.
About Cytorex Biosciences, Inc.
Cytorex Biosciences, Inc. is a small innovative biotechnology company based in South Florida with a research and development coordination center in Kingwood, Texas focused on the development and research of ionic therapeutic agents, based on Cytoreg® ionic therapeutic technology, for the development of targeted therapeutic agents for the treatment of pathologies such as cancer, autoimmune diseases, neurodegenerative diseases, kidney stones, bacterial-derived pathologies, viruses such as Ebola and SARS-CoV-2 among other pathologies. Cytorex has worldwide intellectual property rights on its technologies, with other new patents pending and others in development. Cytorex Biosciences Inc. is currently in the final stage of the preclinical phase for PRE-IND review by USFDA of its ionic therapeutic agent designed for the treatment of Glioblastoma Multiforme brain tumors.